Cargando…
VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer
Angiogenesis, the sprouting of the existing vascular network to form new vessels, is required for the growth of solid tumors. For this reason, the primary stimulant of angiogenesis, vascular endothelial growth factor-A (VEGF), is an attractive target for tumor therapy. In fact, there are currently n...
Autores principales: | Lynn, Kristi D., Roland, Christina L., Brekken, Rolf A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835113/ https://www.ncbi.nlm.nih.gov/pubmed/24281102 http://dx.doi.org/10.3390/cancers2020970 |
Ejemplares similares
-
Pleiotrophin drives a prometastatic immune niche in breast cancer
por: Ganguly, Debolina, et al.
Publicado: (2023) -
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
por: Roland, Christina L., et al.
Publicado: (2009) -
GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
por: Lynn, Kristi D, et al.
Publicado: (2010) -
Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer
por: Jee, Youn Hee, et al.
Publicado: (2016) -
The role of pleiotrophin and β-catenin in fetal lung development
por: Weng, Tingting, et al.
Publicado: (2010)